Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients
Security and Efficacy of Triple Therapy Including Direct-Acting Antivirals Against Chronic Hepatitis C Infection In HIV-Coinfected Patients In Real-Life Conditions: The Prospective HEPAVIR Cohort.
Sponsor: Complejo Hospitalario Universitario de Huelva
Listed as NCT02057003, this observational or N/A phase trial focuses on Hepatitis C, Chronic and Human Immunodeficiency Virus and remains ongoing. Sponsored by Complejo Hospitalario Universitario de Huelva, it has been updated 6 times since 2012, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jun 2018 — Jan 2021 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
▶ Show 1 earlier version
-
Jan 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Jan 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Complejo Hospitalario Universitario de Huelva
- Complejo Hospitalario de Jaén
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
- Hospital La Línea
- Hospital Poniente
- Hospital Regional de Malaga
- Hospital Torrecárdenas
- Hospital Universitario Central de Asturias
- Hospital Universitario Puerta del Mar
- Hospital Universitario Puerto Real
- Hospital Universitario Reina Sofia de Cordoba
- Hospital Universitario Virgen Macarena
- Hospital Universitario Virgen de la Arrixaca
- Hospital Universitario Virgen de la Victoria
- Hospital Universitario de Canarias
- Hospital Universitario de Gran Canaria
- Hospital Álvaro Cunqueiro
- Valme University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .